PBMJ Open

Optimising gestational weight gain and improving maternal and infant health outcomes through antenatal dietary, lifestyle and physical activity advice: the OPTIMISE randomised controlled trial protocol

Jodie M Dodd,1,2 Andrea R Deussen,1 Jennie Louise3

ABSTRACT

Introduction Obesity represents a significant health burden, and WHO recognises the importance of preventing weight gain and subsequent development of obesity among adults who are within the healthy weight range. Women of reproductive age have demonstrated high rates of weight gain during pregnancy placing them at risk of becoming overweight or obese. We will evaluate the effects of dietary and physical activity advice on maternal, fetal and infant health outcomes, among pregnant women of normal body mass index (BMI).

Methods and analysis We will conduct a randomised controlled trial, consenting and randomising women with a live singleton pregnancy between 10+0 and 20+0 weeks and BMI 18.5–24.9 kg/m2 at first antenatal visit, from a tertiary maternity hospital. Women randomised to the Lifestyle Advice Group will receive three face-to-face sessions (two with a research dietician and one with a trained research assistant) and three telephone calls over pregnancy, in which they will be provided with dietary and lifestyle advice and encouraged to make change using a SMART goals approach. Women randomised to the Standard Care Group will receive routine antenatal care. The primary outcome is infant birth weight >4 kg. Secondary outcomes will include adverse infant and maternal outcomes, maternal weight change, maternal diet and physical activity changes, maternal quality of life and emotional well-being, fetal growth and costs of healthcare. We will recruit 624 women of normal body mass index (BMI), defined as BMI between 18.5 and 24.9 kg/m2. Analyses will be intention to treat with estimates reported as relative risks and 95% CIs.

Ethics and dissemination Ethical approval has been obtained from the Women's and Children's Hospital ethics committee. Findings will be disseminated widely via journal publication and conference presentation(s), and participants informed of results.

Trial registration number ACTRN12614000583640.

INTRODUCTION

Worldwide, more than 1.9 billion adults and 41 million children under the age of 5 years are overweight or obese. Obesity represents a significant healthcare burden, with WHO recognising the importance of preventing weight gain among adults who are within the healthy weight range. Women of reproductive age have demonstrated high rates of gestational weight gain (GWG) among adults who are within the healthy weight range.2 Women of reproductive age have demonstrated high rates of gestational weight gain (GWG) during pregnancy and postpartum weight retention (PPWR),3 and therefore represent an ‘at-risk’ population.

The Institute of Medicine (IoM) has reviewed the considerable observational literature which is available, recommending GWG between 11.5 and 16.0 kg for pregnant women of normal body mass index (BMI), defined as BMI between 18.5 and 24.9 kg/m2.4 Weight gain in excess of these recommendations is well recognised as a significant risk factor for adverse maternal and infant outcomes during pregnancy and childbirth, even among women of normal BMI,5–8 and more than doubles a woman’s risk of PPWR.9 Indeed, more than 70% of women with a BMI retain more than 5 kg weight up to 1 year after birth,10 11 contributing to an increase in interpregnancy BMI, an increased risk of adverse outcomes in a subsequent pregnancy and longer-term risk of obesity.12–14 There is

Strengths and limitations of this study

- Robust evaluation of the effects of a dietary and lifestyle intervention during pregnancy for women of normal body mass index (BMI).
- Prospectively measured and calculated height, weight and BMI at the time of the first antenatal booking visit.
- A wide range of clinically relevant maternal and infant health outcomes will be reported.
also increasing evidence that excessive GWG increases the chance of high infant birth weight, with both factors independently associated with an increased risk of child obesity.\textsuperscript{15,16} Specifically, the risk of early childhood obesity increases by a factor of 1.08 (95% CI 1.03 to 1.14) per kilogram of maternal weight gained above the recommendations.\textsuperscript{18} All of these factors combine to create a vicious cycle in which the intergenerational effects of obesity are perpetuated.\textsuperscript{19}

While there is extensive observational literature defining the pregnancy and childbirth complications associated with excessive GWG and PPWR for women of normal BMI, there is limited information describing effective interventions. Our systematic review of the literature identified 12 randomised controlled trials (RCTs) of 2713 pregnant women, who were recruited across all BMI categories.\textsuperscript{20} Of these trials, eight specifically identified 1048 women to be of normal BMI, of which only five reported clinical outcomes for women of normal BMI (714 women).\textsuperscript{20} Women of normal BMI who received an antenatal intervention gained less weight (1.25 kg; 95% CI −2.39 to −0.11) than those women receiving standard antenatal care and were less likely to have weight gain above the IoM recommendations (relative risk (RR) 0.72; 95% CI 0.60 to 0.86; five studies, 714 women).\textsuperscript{20} However, the effect on clinical pregnancy outcomes was less clear (two studies, 243 women), and only two studies reported PPWR at 8 weeks and 6 months after birth.\textsuperscript{20} While there was a modest overall effect on GWG, effects on clinical pregnancy and birth outcomes have been poorly reported to date, and there is no information relating to longer-term effects on both maternal and child health.

The aims of the OPTIMISE randomised trial are to evaluate the effects of dietary and physical activity advice on maternal, fetal and infant health outcomes, among pregnant women of normal BMI.

**METHODS AND ANALYSIS**

**Study design**

RCT.

**Inclusion criteria**

Women with a singleton, live gestation between 10\textsuperscript{10} and 20\textsuperscript{10} weeks who are of normal BMI (BMI 18.5 to 24.9 kg/m\textsuperscript{2}) at their first antenatal visit will be eligible to participate.

**Exclusion criteria**

Women with a multiple pregnancy or who have type 1 or 2 diabetes who were diagnosed prior to pregnancy will be excluded from participation.

**Trial entry**

Eligible women will be identified in the antenatal clinic of the Women’s and Children’s Hospital, given the trial information sheet and counselled by a researcher, before obtaining informed written consent. Randomisation will occur using the computer-based randomisation service in the Discipline of Obstetrics and Gynaecology, The University of Adelaide. Recruitment commenced in June 2014, and the study is ongoing.

The randomisation schedule will use balanced variable blocks and will be prepared by an investigator not involved with recruitment or clinical care. There will be stratification of women according to parity (0 vs 1 or more). Eligible women will be randomised to either the *Lifestyle Advice Group* or the *Standard Care Group*. Blinding of participants is not possible given the nature of the intervention. Where possible, antenatal care providers, outcome assessors and data analysts will be blinded to treatment allocation.

**Treatment schedules**

Women who are randomised to the *Lifestyle Advice Group* will receive three individual face-to-face sessions during pregnancy, with two provided by the dietitian shortly after trial entry and again at 28 weeks of gestation, and one provided by a research assistant at 36 weeks of gestation. Women will also receive three telephone calls from the research assistant at 20, 24 and 32 weeks of gestation. The dietary advice provided will be individually tailored, consistent with current Australian dietary standards,\textsuperscript{21} and based on our experience with the LIMIT randomised trial.\textsuperscript{22 23} Recommendations and dietary targets will be individualised, taking into account each woman’s basal metabolic rate and activity levels.\textsuperscript{24} The dietary intervention will maintain a balance of carbohydrates, fat and protein, while specifically encouraging women to reduce their intake of energy dense and non-core foods high in refined carbohydrates and saturated fats, while increasing their intake of fibre, and to consume two serves of fruit, five serves of vegetables and three serves of dairy each day.\textsuperscript{21–23}

Tailoring of the intervention will be informed by stage theories of health decision making that propose that individuals progress through a series of cognitive phases when undertaking behavioural change.\textsuperscript{25} Initially, there will be a planning session with a research dietitian, in which women will be provided with written dietary and activity information, an individual diet and physical activity plan, recipe book and example menu plans. Women will be encouraged to set achievable goals for dietary and physical activity change, supported to make these lifestyle changes and to self-monitor their progress, using a SMART goals approach. Women will be encouraged to involve their partner or significant support person in these sessions. These principles will be reinforced at subsequent face-to-face visits with the dietitian and research assistant and during the telephone contacts.\textsuperscript{22 23}

Women who are randomised to the *Standard Care Group* will receive their antenatal care according to their local hospital practice, which does not currently include information relating to dietary intake and physical activity during pregnancy.
All women will be asked to complete a food frequency questionnaire, physical activity diary and quality of life assessments at trial entry, 28 and 36 weeks of gestation and 6 months postpartum. Their weight will be recorded at trial entry, at 28 weeks of gestation and at 36 weeks of gestation or nearest to birth. All women will be encouraged to attend for a research ultrasound at 28 and 36 weeks of gestation that does not constitute routine clinical care to monitor fetal growth and well-being. After birth, information will be obtained relating to birth and infant outcomes from the case notes by the research assistant, who will remain blinded to the woman’s allocated treatment group. The primary trial outcome is the incidence of infants with study endpoints allocated treatment group. A research assistant, who will remain blinded to the woman’s well-being, will be encouraged to attend for a research ultrasound at 28 and 36 weeks of gestation or nearest to birth. All women will be asked to complete a food frequency questionnaire, physical activity diary and quality of life assessments at trial entry, 28 and 36 weeks of gestation and 6, 12 and 18–24 months after birth (Harvard Semi-quantitative Food Frequency Questionnaire29 30 and the Short Questionnaire to Assess Health-enhancing physical activity31; maternal weight changes including total GWG, average weekly gestational gain, GWG below/within/above IoM recommendations,14 maternal weight at 6, 12 and 18–24 months after birth to calculate PPWR, maternal changes in diet and physical activity as measured by questionnaires completed by the woman at trial entry, 28 and 36 weeks of gestation and 6, 12 and 18–24 months after birth (Harvard Semi-quantitative Food Frequency Questionnaire29 30 and the Short Questionnaire to Assess Health-enhancing physical activity31; maternal quality of life and emotional well-being as measured by questionnaires completed by the woman at 6 months postpartum relating to quality of life (as measured using the Short Form-12 Health Survey Questionnaire),32 preferences for treatment, satisfaction with care, anxiety (as measured by the Short Form Spielberger State Trait Inventory33) and depression (as measured by the Edinburgh Postnatal Depression Scale34). Women will be asked a series of questions about their satisfaction with the intervention, using items modified from a previous childbirth questionnaire35; fetal growth and well-being at 28 and 36 weeks of gestation assessed by ultrasound (fetal biometry, estimated weight, liquor volume, umbilical artery Doppler waveform and adiposity)36; costs of healthcare: the primary measure of outcome for the economic analysis will be the cost per live birth. Resource use will include the provision of the dietary intervention and direct costs of healthcare (expected average clinic fees, the frequency and duration of general practitioner and antenatal visits, as well as inpatient admissions), determined by hospital outpatient visits, inpatient admissions and published data sets including Pharmaceutical Benefits Scheme (PBS), Medical Benefits Schedule (MBS) and Australian Refined Diagnosis Related Groups cost weights. Mean costs and effectiveness between treatment groups will be compared and incremental cost-effectiveness ratios and CIs presented. For varying threshold values of cost-effectiveness, acceptability curves will be presented as described previously.37 An assessment of the sensitivity of the results to variation in measured resource use, effectiveness and/or unit costs will be undertaken using appropriate one-way and multi-way sensitivity analyses, as described previously.37 Sample size estimation

The primary clinical endpoint is the incidence of infants born with birth weight >4 kg, with an estimated incidence in women eligible for this trial of 8.72%.38 To detect a difference from 8.72% to 3.89% (alpha 0.05; power 70%), we will recruit a total of 624 women. This sample size will
be powered (70%) to detect the differences in secondary outcomes as detailed in table 1 below.

### Analysis and reporting of results

The initial analysis will examine baseline characteristics of all randomised women, as an indication of comparable treatment groups, and include maternal age, parity, race, height, weight, smoking history, obstetric history and previous gestational diabetes. Primary and secondary outcomes will be analysed on an ‘intention to treat’ basis, according to treatment allocation at randomisation. RRs and 95% CIs will be reported for the major outcomes, and the number needed to treat to benefit or harm calculated. Regression techniques will examine the influence of prognostic factors on the major outcomes.

As the lead investigator, JMD will have access to the data and acts as a guarantor to the final data set. The trial manager (ARD) and statistician (JL) will have access to the data, and the statistician (JL) will be responsible for the development of the statistical analysis plan, prior to the conduct of any statistical analyses.

### ETHICS AND DISSEMINATION

#### Data management

All information obtained from this study will remain strictly confidential. While the results of the study will be published, no data will be presented to allow the identification of individual women. Data will be stored in a locked filing cabinet or on password protected computer file and accessible only by the study team.

We have previous experience recruiting women for lifestyle intervention trials in this setting and will consider adding further sites as required. Women who withdraw from ongoing participation after randomisation will be asked for consent to use the data already collected prior to withdrawal, including birth outcomes where possible.

Following completion of the relevant statistical analyses, manuscripts will be prepared for publication, with subsequent presentation of results at relevant scientific and clinical meetings. Participants will be notified of the findings of the trial. The findings of this trial will contribute to the currently available literature regarding the effect of antenatal dietary and lifestyle interventions for women of normal BMI and to the development of evidence-based clinical practice guidelines.

Recruitment commenced in June 2014. We expect to have completed data collection and data cleaning by April 2018. The final results of the trial will be published in international peer-reviewed journals.

### Ethical approval

A Data and Safety Monitoring Board (DSMB) will monitor efficacy (or futility) and adverse effects. Based on these considerations, the DSMB may recommend that the protocol be modified or that the OPTIMISE trial be terminated. The DSMB will consist of experts in relevant obstetrics, neonatology and research methodology. All adverse events involving women and infants enrolled in the trial will be reviewed by a multidisciplinary committee, who will be blinded to treatment allocation, in order to clarify cause. These data will be made available for the DSMB.

### REFERENCES

1. World Health Organisation. Overweight and obesity fact sheet June 2016. Geneva, Switzerland: World Health Organisation, 2016.

2. World Health Organisation. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. Geneva, Switzerland: World Health Organisation, 2013.

3. Cameron AJ, Welborn TA, Zimmet PZ, et al. Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 2003;178:427–32.

4. Institute of Medicine. Weight gain during pregnancy: reexamining the guidelines. In: Rasmussen KM, Yaktine AL, eds. Washington D.C: The National Academies Press, 2009.

5. Dodd JM, Grivell RM, Nguyen AM, et al. Maternal and perinatal health outcomes by body mass index category. Aust N Z J Obstet Gynaecol 2011;51:136–40.

6. Callaway LK, Prins JB, Chang AM, et al. The prevalence and impact of overweight and obesity in an Australian obstetric population. Med J Aust 2006;184:56–9.

7. Cedergren M. Effects of gestational weight gain and body mass index on obstetric outcome in Sweden. Int J Gynaecol Obstet 2006;93:269–74.
8. Cedergren MI. Optimal gestational weight gain for body mass index categories. *Obstet Gynecol* 2007;110:759–64.

9. Rong K, Yu K, Han X, et al. Pre-pregnancy BMI, gestational weight gain and postpartum weight retention: a meta-analysis of observational studies. *Public Health Nutr* 2015;18:2172–82.

10. Ma D, Szeto IM, Yu K, et al. Association between gestational weight gain according to prepregnancy body mass index and short postpartum weight retention in postpartum women. *Clin Nutr* 2015;34.

11. Nehring I, Schmoll S, Beyerlein A, et al. Gestational weight gain and long-term postpartum weight retention: a meta-analysis. *Am J Clin Nutr* 2011;94:1225–31.

12. Amorim AR, Rössner S, Neovius M, et al. Does excess pregnancy weight gain constitute a major risk for increasing long-term BMI? *Obesity* 2007;15:1278–86.

13. Kac G, Benicio MH, Velásquez-Méndez G, et al. Gestational weight gain and prepregnancy weight influence postpartum weight retention in a cohort of Brazilian women. *J Nutr* 2004;134:661–6.

14. Oken E, Taveras EM, Kleinman KP, et al. Gestational weight gain and child adiposity at age 3 years. *Am J Obstet Gynecol* 2007;196:322–8.

15. Rooney BL, Mathisson MA, Schauberger CW. Predictors of obesity in childhood, adolescence, and adulthood in a birth cohort. *Matern Child Health J* 2011;15:1166–75.

16. Oken E, Taveras EM, Kleinman KP, et al. Gestational weight gain and child adiposity at age 3 years. *Am J Obstet Gynecol* 2007;196:322–8.

17. Wrotniak BH, Shults J, Butts S, et al. Gestational weight gain and risk of overweight in the offspring at age 7 y in a multicenter, multiethnic cohort study. *Am J Clin Nutr* 2008;87:1818–24.

18. O’Hare AM, Dolan LM, Dunne EA, et al. Gestational weight gain and obesity--a vicious circle across generations. *Int J Obes* 2010;34:67–74.

19. Cnattingius S, Villamor E, Lagerros YT, et al. Health-physical activity intervention and maternal quality of life: the LIMIT randomised trial. *BMJ* 2004;329:985–9.

20. Nethery CR, Rabd C, Cross JD, et al. Validation of a semi-quantitative food frequency questionnaire: comparison with a 1-year diet record. *J Am Diet Assoc* 1987;87:43–7.

21. Marteau TM, Bekker H. The development of the 10 item Edinburgh Postnatal Depression Scale - development of the 10 item Edinburgh Postnatal Depression Scale (EDPS). *Brit J Psych* 1987;154:782–6.

22. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30:473–83.

23. Bennett P, Murphy S. The detection, investigation and management of hypertension in pregnancy: full consensus statement. *Aust NZ J Obstet Gynaecol* 2000;40:139–55.

24. Logue J, Thompson L, Romanes F, et al. Management of obesity: summary of SIGN guidelines. *BMJ* 2010;340:c154.

25. Bennett P, Murphy S. *Psychology and health promotion.* Buckingham: Open University Press, 1997.

26. Australian and New Zealand Neonatal Nurses. ANZNN data dictionary 2009. 20. http://www.preru.unsw.edu.au/PRERUWeb. nsl/page/ANZNN

27. Brown MA, Hague WM, Higgins J, et al. The detection, investigation and management of hypertension in pregnancy: full consensus statement. *Aust NZ J Obstet Gynaecol* 2000;40:139–55.

28. Willett WC, Reynolds RD, Cottrell-Hoehner S, et al. Validation of a semi-quantitative food frequency questionnaire: comparison with a 1-year diet record. *J Am Diet Assoc* 1987;87:43–7.

29. Cnattingius S, Villamor E, Lagerros YT, et al. Health-physical activity intervention and maternal quality of life: the LIMIT randomised trial. *BMJ* 2004;329:985–9.

30. Oken E, Taveras EM, Kleinman KP, et al. Gestational weight gain and child adiposity at age 3 years. *Am J Obstet Gynecol* 2007;196:322–8.

31. Wrotniak BH, Shults J, Butts S, et al. Gestational weight gain and risk of overweight in the offspring at age 7 y in a multicenter, multiethnic cohort study. *Am J Clin Nutr* 2008;87:1818–24.

32. Schack-Nielsen L, Michaelsen KF, Gamborg M, et al. Gestational weight gain in relation to offspring body mass index and obesity from infancy through adulthood. *Int J Obes* 2010;34:67–74.

33. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). *Br J Clin Psychol* 1992;31:301–6.

34. Cox JL, Holden JM, Siegal KK. Detection of postnatal depression - development of the 10 item Edinburgh Postnatal Depression Scale (EDPS). *Brit J Psych* 1987;154:782–6.

35. O’Brien CM, Grivell RM,を行う求人について情報を更新する。*Antenatal lifestyle advice for overweight or obese women who are overweight or obese and the* *Medical Care* 1992;30:473–83.

36. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). *Br J Clin Psychol* 1992;31:301–6.

37. Grivell RM, Yelland LN, Deussen A, et al. Antenatal dietary and lifestyle advice for women who are overweight or obese on maternal quality of life: the LIMIT randomised trial. *Acta Obstet Gynecol Scand* 2006;85:259–69.

38. Logue J, Thompson L, Romanes F, et al. Management of obesity: summary of SIGN guidelines. *BMJ* 2010;340:c154.